Skip to content
Search

Latest Stories

Supply disruption expected for Evorel 75 & 50

There will be intermittent supply of Evorel 75 and Evorel 50 during the first half of this month following unprecedented demand, drug manufacturer Theramex said on Friday (July 3).

Other products in Evorel portfolio, Evorel 25, Evorel 100, Evorel Conti and Evorel Sequi are all currently available in market.


CountryProduct NameDates of Availability
UK
  1. Evorel 25
  2. Evorel 50
  3. Evorel 75
  4. Evorel 100
  5. Evorel Conti
  6. EvorelSequi
  1. Available
  2. Intermittent supply first half of July
  3. Intermittent supply first half of July
  4. Available
  5. Available
  6. Available
 

“Since February 2020, we have produced nearly 750,000 packs across the Evorel portfolio. There has been unprecedented demand for all of the products and we are are working with our manufacturing partners to continuously increase capacity in order to ensure that Evorel is readily available to every patient who needs it,” the London-based drug maker noted.

In order to ensure the widest possible reach of the available stock, pharmacists have been informed that Alliance Healthcare have applied monthly quotas to the volume of stock available to individual pharmacists.

If any pharmacy requires additional stock on the quota to fulfill prescriptions, the pharmacists can reach Alliance Healthcare customer service, the company added.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less